Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double‐blind, placebo‐controlled study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 3, 2015-03 ,pp. : 304-308

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)

By  

CANCER, Vol. 124, Iss. 3, 2018-02 ,pp. : 606-616

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antihypertensive Treatment in Postmenopausal Women: Results from a Prospective, Randomized, Double-Blind, Controlled Study Comparing an ACE Inhibitor (Moexipril) with a Diuretic (Hydrochlorothiazide)

By  

Cardiology, Vol. 89, Iss. 4, 2008-10 ,pp. : 271-276

Karger

Access to resources Recommend Favorite

Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 7, 2015-09 ,pp. : 685-692

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 2, 2015-02 ,pp. : 152-160

John Wiley & Sons Inc

Access to resources Recommend Favorite